Table 2.
Patient-based analysis
| Breast cancer subtype | Site lesion | 18F-FDG | 68Ga-PSMA-11 |
|---|---|---|---|
| LUM A | Local | 4/4 | 2/4 |
| Lymph-node disease | 4/4 | 1/4 | |
| metastatic disease | 3/3 | 2/3 | |
| LUM B HER2- | Local | 4/4 | 2/4 |
| Lymph-node disease | 2/2 | 1/2 | |
| metastatic disease | 3/3 | 3/3 | |
| LUM B HER2+ | Local | 2/2 | 2/2 |
| Lymph-node disease | 1/1 | ||
| metastatic disease | 2/2 | 2/2 | |
| HER-2 overexpression | Local | 6/6 | 5/6 |
| Lymph-node disease | 5/5 | ||
| metastatic disease | 4/4 | 4/4 | |
| TPN | Local | 5/5 | 5/5 |
| Lymph-node disease | 5/5 | 5/5 | |
| metastatic disease | 3/3 | 3/3 |
Abbreviations: LUM = molecular subtypes of breast cancer including luminal A and luminal B; HER-2 = human epidermal growth factor receptor 2; TPN = triple negative breast cancer.